Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 9/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19101372 | 0.77 | SLC18A3 (0.55) | SLC18A3GRIN2BDRD2SIGMAR1CYP2D6 | |
| SCHEMBL11062207 | 0.77 | SLC18A3 (0.55) | SLC18A3GRIN2BDRD2SIGMAR1CYP2D6 | |
| SCHEMBL1477625 | 0.77 | SLC18A3 (0.58) | SLC18A3GRIN2BDRD2SIGMAR1CYP2D6 | |
| SCHEMBL96849 | 0.77 | SLC18A3 (0.55) | SLC18A3GRIN2BDRD2SIGMAR1CYP2D6 | |
| SCHEMBL7344869 | 0.77 | SLC18A3 (0.55) | SLC18A3GRIN2BDRD2SIGMAR1CYP2D6 | |
| SCHEMBL54932 | 0.77 | DRD2 (0.63) | SLC18A3GRIN2BDRD2SIGMAR1CYP2D6 | |
| SCHEMBL18123291 | 0.77 | GRIN2B (0.56) | SLC18A3GRIN2BDRD2SIGMAR1CYP2D6 | |
| SCHEMBL14252408 | 0.77 | SLC18A3 (0.55) | SLC18A3GRIN2BDRD2SIGMAR1CYP2D6 | |
| SCHEMBL41763 | 0.77 | — | — | |
| SCHEMBL190417 | 0.77 | SLC18A3 (0.67) | SLC18A3GRIN2BDRD2SIGMAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273765-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7271165-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070142392-A1 | Uses of rifamycins | ACTIVBIOTICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142392-A1 | Uses of rifamycins | TNF, TLR6, IL6 | SLC18A3 4841/4885GRIN2B 4597/4885DRD2 4605/4885 |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | SLC18A3 4689/4885GRIN2B 4758/4885DRD2 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.